Trial register facet
Phase 1 trial records — page 2
226 records at phase 1.
Showing 0 records on this page
Records
226 documents · page 2 of 10
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| DREAMS-2-PKprogramme record | Mazdutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| SURVO-PH2-MASH-RENAL-IMPprogramme record | Survodutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| PETRE-PH1B-BIOMARKERprogramme record | Petrelintide | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| REIMAGINE-1-PKprogramme record | Amycretin | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| FLOW-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| PETRE-PH1B-ELDERLYprogramme record | Petrelintide | Phase 1 | Reported | Randomised, double-blind, placebo-controlled | — | 2024 | Very low |
| REIMAGINE-1-DDIprogramme record | Amycretin | Phase 1 | Reported | Randomised crossover | — | 2024 | Very low |
| PETRE-PH1B-PKprogramme record | Petrelintide | Phase 1 | Reported | Phase 1 ascending dose | — | 2024 | Very low |
| STEP-HFpEF-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-RENAL-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-T2D-HEPATIC-IMPprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| STEP-HFpEF-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| SURMOUNT-2-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-T2D-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| ORFO-PH2-T2D-DDIprogramme record | Orforglipron | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| SURMOUNT-2-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| RETA-PH2-OBESITY-DDIprogramme record | Retatrutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-T2D-PKprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| ORFO-PH2-T2D-PKprogramme record | Orforglipron | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| RETA-PH2-OBESITY-HEPATIC-IMPprogramme record | Retatrutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
page 2 of 10